Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez

really Lily's gain. Let's ask Guggenheim, managing director and pharma analyst Sheamus Fernandez. Sheamus, thanks for coming back on.Um, if one's winning, I don't want to say one's losing, but if one is doing better than the other, does that mean people are shifting their GLP1 drug of choice. >> Yeah, it's a great question, Brian. Look, I I don't think that we're seeing a lot of market shifts just yet uh in terms of their their drug of choice. We're seeing a huge market expansion in general occur.I think th ...